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The incidence of ectopic pregnancy is on the rise and accounts for
approximately 2% of all pregnancies in the United States. Incidence has
increase six-fold over the last two decades.! Ectopic pregnancy is the
leading cause of maternal mortality in the United States in the first
trimester, and accounted for thirty-five deaths in 1997. 2 But beyond the
medical implications of ectopic pregnancy, it also has ethical
considerations that need to be taken into account. The Ethical and
Religious Directives for Catholic Health Care Services states that:
"Catholic health care ministry witnesses to the sanctity of human life 'from
the moment of conception until death."'3 Yet in contrast to this, current
medical practice for the treatment of ectopic pregnancy consists of
modalities that could constitute a direct abortion. What is a Catholic
physician or hospital to do in treating a woman with an ectopic pregnancy?
How are we to be witnesses to the sanctity of life in this tragic problem?
This presentation is intended to address the medical and ethical concerns in
the treatment of ectopic pregnancy.

Ectopic Pregnancy Defined
An ectopic pregnancy is the implantation of the embryo outside of its
normal intrauterine site. Subsequent growth of the embryo occurs for a
variable length of time before the clinical signs and symptoms of an
ectopic pregnancy become manifest, depending on the site of implantation.
Sites of ectopic implantation are the fallopian tube (95-97%), insterstitiaV
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cornual angle (2-4%), ovary (0.5 %), abdominal cavity (0.3 %), or cervix
(0.1 %).4 Clinical signs and symptoms occur at about six to eight weeks
after the last menstrual period in a tubal pregnancy and at ten to twelve
weeks in an interstitial/cornual angle pregnancy. In the majority of cases of
ectopic pregnancy, presenting symptoms are secondary to tubal rupture or
tuballeaking.4 Abdominal ectopics can proceed to viability in 11 - 45 % of
cases, but maternal mortality from massive hemorrhage is not uncommon .5.6
Etiology of ectopic pregnancy includes tubal damage secondary to
pelvic inflammatory disease, intrauterine devices, progesterone-only pills,
two or more elective abortions, ART, previous ectopic pregnancy, tubal
scarring from any cause, and hormonal abnormalities. Evidence of pel vic
inflammatory disease is present in up to 77 % of fallopian tubes with an
ectopic pregnancy.?
Due to the advancement of the diagnostic studies available, the
di agnosis of an ectopic pregnancy is made much earlier in its course than
in years past, and has lead to a decline in maternal mortality. 2 These
diagnostic studies include sensitive ~-HCG assays, trans-vaginal
ultrasound, progesterone assays, and laparoscopy. These di agnostic
advancements have largely replaced the classic triad of pain, bleeding, and
adnexal mass in the definitive diagnosis of ectopic gestation.
The diagnosis of ectopic pregnancy is based upon the accurate
detection of ~-HCG, a hormone produced by the sy ncytiotrophoblasts of
the embryo. ~-HCG levels are detectable in the blood as early as six days
after conception and are always present by twelve days after conception. s
~-HCG levels approximately double every forty-eight hours in early
pregnancy; an abnormal rise of ~-HCG is suggestive of mi scarriage and
ectopic pregnancy.
At levels over 2000 mIU/ml, a gestational sac should be seen in the
uterus by trans-vaginal ultrasound , although in cases of multiple gestation
there can be a delay of visualization of the gestational sac. 9 Progesterone
levels are also useful predictors of normal intrauterine gestations, ectopic
pregnancy, and spontaneous abortion, especially when used in conjunction
with ~-HCG levels and tran s-vaginal ultrasound. Progesterone level s <5
ng/ml are highly suggestive of a mi scarriage or ectopic pregnancy. 10 Transvaginal ultrasound is a highly useful tool in the diagnosis of early
intrauterine pregnancies, and when used in conjunction with ~-HCG
levels, gives physicians the ability to often make the diagnosis of ectopic
pregnancies without the need for laparoscopy or laparotomy. Intrauterine
gestational sacs can be seen by trans-vaginal ultrasound as early as sixteen
days post conception, II and embryonic cardiac activity can be seen shortly
thereafter.
Unlike years past, most cases of ectopic pregnancy today are
diagnosed before tubal rupture has occurred, without the need for surgical
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exploration to stop life-threatening bleeding. The early diagnosis has also
lead to the trend to treat ectopic pregnancy by way of laparoscopy or with
medication. Current treatment modalities for ectopic pregnancy are: 1)
expectant management; 2) surgical management (salpingostomy or
salpingectomy); 3) medical management (methotrexate).
Expectant management is a sound option for early ectopic pregnancies
that have relatively low ~-HCG levels. The ectopic tissue gradually
degenerates over time and is eventually reabsorbed. Criteria for expectant
management are: stable vital signs; ~-HCG levels less than 1,000-2,000
mlU/ml and falling; mass size less than 2-4 centimeters; and less than 50
ml of hemoperitoneum. 12.13 Successful resolution rates range from 60-64%
if the above criteria are met. 12.13 If levels are above 2,000 mID/mI, the
failure rate is 93.3 %.13 Benefits are that the patient avoids any surgical or
medical treatment with the inherent risks. Risks include tubal rupture and
failure for spontaneous resolution and the need for further intervention.

Three Types of Management
The first type of surgical management is laparoscopic salpingostomy,
which is now deemed the surgery of choice for the treatment of an
unruptured ectopic pregnancy.14 A linear incision is made in the antimesenteric portion of the fallopian tube, and the gestational tissue is
removed. The tube is left open to heal by secondary intention, hopefully
allowing tubal patency and function to be preserved. Future pregnancy
rates are reported to be between 50 - 67%, but repeat ectopics occur about
7 -16% of the time. IS Risks of linear salpingostomy are that trophoblastic
ti ssue may be left behind leading to a condition of a "chronic ectopic ',
where trophoblastic tissue continues to remain viable. A chronic ectopic
occurs about 5-20% of the time following linear salpingostomy. IS
The second type of surgical management is salpingectomy. Partial or
total salpingectomy is still the procedure of choice in ruptured ectopic
pregnancy.4.S Part or all of the tube is removed via the laparascope or
laparotomy. Future pregnancy rates for patients undergoing salpingectomy
depend on the condition of the remaining tube, and range between 3080%.1 5There is no chance of persistent ectopic. Re-anastamosis of the tube
may also be offered in patients who undergo a partial salpingectomy, either
at the initial surgery or at a later time.
The third type of management for ectopic is medical management,
which involves the systemic injection of methotrexate. Methotrexate is an
anti-metabolite, and its site of action is the rapidly dividing outer
trophoblastic tissue of the embryo. After the trophoblastic tissue is
eliminated, reabsorption of the tissue occurs and hopefully tubal patency
and function are preserved. Toxicity of methotrexate can occur in 20-30%
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of patients, depending on whether single or multiple dose regimens are
used. 4 Methotrexate fails to eliminate the ectopic pregnancy in 5-29% of
cases. IS Failure is more likely to occur if cardiac activity is present, !)-HCG
levels are >3,000-5,000 mIU/ml, and progesterone levels are >10 ng/
ml. I6,17,18 Patients who received systemic methotrexate therapy had a more
negative impact on their quality of life (secondary to the side-effects of the
medication) than did patients undergoing surgical management. 19
Methotrexate therapy would be preferred by most patients, even with the
negative side-effects, but only as part of a completely non-surgical
management strategy,zo Future pregnancy rates following methotrexate are
comparable to salpingostomy (50-67%).
In the current management strategies for ectopic pregnancy,
controversy still exists over the best treatment modality. Despite the push
by many gynecologists for tube-sparing surgery (salpingostomy) or
medical management (methotrexate) of ectopic pregnancy, these methods
have not been shown to be superior to salpingectomy in terms of future
pregnancy rates. 21
The condition of the contra-lateral tube and a history of previous
tubal surgery are the most important factors in determining subsequent
pregnancy rates, not the treatment modality chosen.22,23If the contra-lateral
fallopian tube was normal and there is no past history of tubal surgery,
pregnancy rates are about 70%. If the contra-lateral fallopian tube is
abnormal, the pregnancy rates are only 30-40%.22.23 One advantage of
salpingectomy is that it avoids any potential of a chronic ectopic. In a
patient with an ectopic pregnancy in her only remaining tube, however,
tube-sparing surgery, methotrexate, or partial salpingectomy with reanastamosis (by surgeons with proper training) are the only options that
allow for preservation of future fertility. An advantage of methotrexate is
that it offers the patient a completely non-surgical intervention for ectopic
pregnancy, which is an attractive option for some patients. 2o
The Catholic teaching with regard to ectopic pregnancy places the
life of the mother and the life of the unborn child on an equal plane from
the moment of conception. "No physician or moralist would admit that it is
lawful to kill the mother in order to save the life of the child; so also it is
unlawful to kill the child in order to save the life of the mother."24
Three directives are stated in the Ethical and Religious Directivesfor
Catholic Health Care Services that apply to ectopic pregnancy. Directive
47 states: "Operations, treatments, and medications that have as their direct
purpose the cure of a proportionately serious pathological condition of a
pregnant woman are permitted when they cannot be safely postponed until
the unborn child is viable, even if they result in the death of the unborn
child."3 Directive 48 states: "In case of extra-uterine pregnancy, no
intervention is morally licit which constitutes a direct abortion."3 What
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constitutes a direct abortion is stated in Directive 45. "Abortion (that is, the
directly intended tennination of pregnancy before viability or the directly
intended destruction of a viable fetus) is never pennitted. Every procedure
whose sole immediate effect is the termination of pregnancy before
viability is an abortion, which, in its moral context, includes the interval
between conception and implantation of the embryo."3 Essentially, the
directives state that any treatment of an ectopic pregnancy is morally
permissible as long as it does not cause a direct abortion, even though it
may result in an indirect abortion.
How then do we treat the maternal life-threatening condition of an
ectopic pregnancy while not causing a direct abortion? Catholic ethicists
have used the principle of double effect to explain the licitness of
salpingectomy in the treatment of ectopic pregnancy. The principle of
double effect states: 1) The action, considered by itself and independently
of its effects, must not be evil; 2) The evil effect must not be the means of
producing the good effect; 3) The evil effect is sincerely not intended, but
merely tolerated; 4) There must be a proportionate reason for performing
the action, in spite of its evil consequences. 25 The principle applies to
ectopic pregnancy in the following way. The removal by salpingectomy of
a pathologically diseased tube is not an evil action of itself. The death of
the embryo (the evil effect) does not produce the saving of the mother's life
(the good effect). The evil effect of the death of the embryo is not intended.
The life-saving procedure for the mother is proportionate to the loss of the
embryo. On the other hand, salpingostomy and methotrexate have been
seen as direct attacks on the embryo, and thus have not been viewed as licit
treatments.

Recent Debate on Salpingostomy and Methotrexate
Recently, a debate has surfaced in the Catholic ethical literature over
whether salpingostomy and methotrexate can be legitimately used in the
treatment of ectopic pregnancy. Rev. Albert Moraczewski in the June and
August 1996 issues of Ethics and Medics gave arguments in favor of the
legitimacy of salpingosotmy and methotrexate in the treatment of ectopic
pregnancy.26.27 His arguments state that both procedures essentially act by
causing an indirect abortion, which if true would be morally acceptable
options. His argument in favor of salpingostomy states that "to remove the
pathological tissue in such a manner that part of the tubal wall remains."26
Rev. Moraczewski is essentially arguing that a salpingostomy is actually
more of a "micro" partial salpingectomy. "This maneuver extracts a sizable
amount of damaged tubal tissue ... the embryo proper is also removed."26
This argument does not apply for the following reasons. First, Stock27 in
his study of 110 tubal gestations found that growth of the ectopic occurs in
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mostly an intra-luminal location. In a salpingostomy, the incision is made
into the tubal lumen, and the ectopic gestation is grasped and usually easily
expressed out of the lumen, and "care should be taken to avoid trauma to
the mucosa."4 The maneuver is intended to remove only the ectopic
gestation, not a "sizable" amount of the tube. Also, salpingostomy works
because trophoblastic tissue has a loose "attachment" to maternal tissue
during the first trimester. True "attachment" to maternal tissue actually
occurs only in the second trimester. 28 The salpingostomy procedure
essentially only removes the ectopic pregnancy itself, not damaged tubal
tissue.
Rev. Moraczewski's argument in favor of the use of methotrexate
basically states that the intention is to "stop the destructive action of the
trophoblastic cells," with the unintended effect being the death of the
embryo.29 The trophoblastic layer (the future placenta) of the embryo is the
largest functioning organ of the embryo, and remains so until delivery of
the infant. The trophoblast is just as integral to the life of the embryo as the
heart is at this time. A direct attack on the trophoblast with methotrexate
would be equivalent to a direct attack on the heart with potassium chloride.
Dr. William May, in the March 1998 issue of Ethics and Medics ,
gave arguments against the use of salpingostomy and methotrexate, stating
that they would constitute a direct abortion. Dr. Eugene Diamond, in the
August, 1999 iss ue of the Linacre Quarterly, gives an excellent paper on
the topic of ectopic pregnancy, and also sides against the use of
salpingostomy and methotrexate.
Salpingostomy and methotrexate are interventions which constitute a
direct abortion, but only when a living embryo is present inside the
trophoblast. If an embryo never develops or has developed but is now
"dead," then salpingostomy and methotrexate would constitute licit means
of treatment of ectopic pregnancy. In order to understand this concept
better, a review of basic embryology is necessary, as well as a concept of
what constitutes human death before heart activity is present in the embryo.
Fertilization of the ovum by the sperm usually occurs in the
ampullary portion of the fallopian tube. 3D The whole process of
fertilization, with the combining of the chromosomal material, takes about
twenty-four hours to complete. 30
This one cell human life is called the zygote. 3D This zygote begins to
divide into daughter cells called blastomeres, shortly after fertilization is
completed. Over the next two to three days, while being propelled through
the fallopian tube by ciliary action and peristalsis, the blastomeres continue
to divide.3D Up to the eight to sixteen cell stages, all the blastomeres are
totipotential , that is that each one is capable of forming an entire new
human life, as in the case of monozygotic twins.
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When the cells number twe lve to fifteen , the name morula is used.3D
The morula reaches the uterus o n about day three or four after
fertilization. 3D A fluid-filled cavity begins to form in the morula, causing
the blasto meres to form into an outer cell mass and an inner cell mass .3D
The outer cell mass or trophobl ast will form the chorion and future
placenta. 3D The blastomeres of the inner cell mass will give ri se to the body
structure, the amnion, and the yolk sac. 3D This is a very important stage of
differe ntiation, which will be ex panded upon later. The bl astocyst freefloats in the uterine cavity for the next three days, continuing to grow and
divide, slowly shedding the ace llul ar covering called the zona pellucida. 30
By the sixth day after fertilization , the outer layer of the trophoblast
beg ins to implant into the uterine cavity. 30 The total implantation process
into the endometrial lining takes until the twelfth to thirteenth day after
fertilization. 3D By day fourteen , the primary chorionic villi start to develop
and the entire blastocyst measures about 3-4 millimeters. 3D.3 1Rapid growth
of the trophoblast and the body of the embryo occurs now so that by postconception day twenty-one, the embryonic body measures about 1.5-3.0
millimeters and the chorionic sac measures about 4-5 mm .31 By postconception day s twenty-one to twenty-two, embryonic cardiac activity is
present,3Dand can be detectable by trans-vaginal ultrasound almost as early
as it appears. 32 By the twenty-e ighth day after conception (s ix weeks si nce
the first day of the last men strual period on a twenty-eight day cycle), the
embryonic body measures 4-6 millimeters in size and the chorionic sac
measures 1.5 centimeters .32 The embryonic body now has visible upper
and lower limb buds, otic pits (future ears) and lens placodes (future lenses
of the eye) are also visible. 3D The embryonic body and trophoblast continue
to grow rapidl y, and by the end of the e ighth week all major organ systems
have formed. 3D At the beginning of the ninth week, the fetal period starts.

Human Life is Now Present
Given this very brief overview of embryology, it is important to
di scuss what constitutes human life and human death before the initi ation
of embryonic cardiac activity. Hum an life is present at the moment of
conception when the zygote is formed, and continues as long as the zygote
is alive. Human life continues to be present in the morula and blastomere
stage of development as long as any of the totipotential blastomeres are
alive, since each can develop into a human being (as in twin s). When the
blastocycst forms, an impOltant differe ntiation takes place, the creation of
the inner and outer cell masses. Once this division takes place, an
outwardly visible organizational structure is made (although it is inwardly
present from the moment of conception). The inner cell mass contains the
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cells that develop into the body structure. The outer cell mass or
trophoblast are the cells which form the future placenta.
The terminology in this area is sometimes very confusing because
the term "embryo" can refer to the entire entity(inner and outer cell
masses) or it can refer to only the embryonic body structure. For purposes
of this paper, after differentiation into the inner and outer cell masses, I will
refer to the body structure as the embryonic body, or sometimes as just the
embryo.
A hierarchy of the parts is now made, with the embryonic body of the
inner cell mass being the central part, and all the other structures being
"organs" of the embryonic body. After the point of division into the outer
and inner cell masses, human life is present as long as the embryonic body
develops and continues to grow. If the inner cell mass does not form, or
forms but stops growing and degenerates, then human life is no longer
present.
Failure of the development of the inner cell mass with continued
growth of the outer cell mass (trophoblast) leads to the clinical entity of a
"blighted ovum", now called an anembryonic pregnancy. Essentially, it is
an empty gestational sac, without embryonic body development. The inner
cell mass for some reason does not develop, while the more resilient outer
cell mass (trophoblast) does. Newer research in this area shows that total
failure of any formation of the inner cell mass cells is probably not exactly
the case. The cells of the inner cell mass do develop for a short time, but
then stop and degenerate,33 while the trophoblastic tissue continues growth
for a variable length of time. This is an important concept, because it has
implications in ectopic pregnancy.
In a tubal pregnancy, implantation of the blastocycst occurs with the
invasion of the inner tubal mucosa by the trophoblast. As the ectopic
grows, there is distention of the fallopian tube, and eventual erosion into
the arteries of the fallopian tube. The distention of the tube and/or the
bleeding causes the symptoms of pain.
Yet unlike the normal embryological development present with an
intrauterine pregnancy, an ectopic pregnancy very often lacks an embryo.34
In a review of the prospectively done pathological studies of ectopic
pregnancy in the literature, an embryo detection rate of only 14-39% was
reported.35,36,37.38.39 The majority of ectopics only contain an empty
chorionic sac, disorganized trophoblastic tissue, or hemorrhage without
identifiable tissue. In the largest of these studies, Poland et al. 35 found only
58 cases which contained an embryo or fetus out of 411 ectopic specimens
(14%). DiMarchi et a1. 36 found 20 out of 131 cases (15%) to have an
embryo present. If the numbers from all the studies are combined, 117 out
of 656 (17)8%) contained an embryo or fetus. Emmrich and Kopping,40 in
a study of 329 tubal pregnancies, found changes in the trophoblastic villi
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that were consistent with blighted ovum or transition to blighted ovum in
84.5% of cases. They suggest that the unfavorable conditions for nidation
in the fallopian tube have a decisive role in the embryo failing to develop in
ectopic pregnancies.
Based on these findings, most ectopic pregnancies have had
embryonic death occur. If embryonic death is present, then any treatment
modality can be used, including salpingostomy and methotrexate. The
criteria for making the diagnosis of embryonic death in ectopic pregnancy
have not been previously defined or well studied (other than lack of cardiac
activity in an identifiable embryo). Can we reliably diagnose which ectopic
pregnancies have a living embryo and which have had embryonic death?

Current Diagnostic Capabilities
The following is an assessment of the current diagnostic capabilities.
Some physicians may disagree with this assessment. In utilizing the current
diagnostic studies of sensitive B-HCG assays, trans-vaginal ultrasound,
and progesterone assays, ectopic pregnancies can be divided into one of
three categories: 1) embryonic life is present; 2) embryonic death has
occurred; and 3) unable to determine if embryonic life or death is present.
First let us consider the case where embryonic life is present based
upon current diagnostic studies. Cardiac activity visualized by ultrasound
in an ectopic pregnancy is a definite sign of embryonic life, thus human life
is present. Cardiac activity is reported to be visualized by trans-vaginal
ultrasound in 15-28% of patients with an ectopic pregnancy.41,42 Brown and
Doubilet43 in a meta-analysis showed that an adnexal embryo with a
heartbeat can be seen in 99 of 492 patients (20.1 %) with a known ectopic
pregnancy. These numbers closely correlate with the probability of finding
an embryo in ectopic pregnancies based on the pathological studies. If a
living embryo is present outside the uterus, it will be most likely found by
trans-vaginal ultrasound.
Second, let us consider the case where embryonic death has occurred
based on current diagnostic studies. When the diagnosis of ectopic
pregnancy (the diagnosis of ectopic pregnancy is a topic in itself and will
not be addressed in detail) is highly suspected based on the clinical
information and embryonic cardiac activity is not seen on trans-vaginal
ultrasound, the following criterion is evidence that embryonic death has
occurred: a progesterone level <5 ng/ml and B-HCG levels that are not
appropriately rising «25% rise over two days).
McCord et al.lO retrospectively studied 3,674 pregnancies and divided
the patients into three pregnancy outcomes: viable intrauterine pregnancy,
spontaneous abortion, and ectopic pregnancy. They found that a viable
intrauterine pregnancy occurred in only 2 of 1,279 patients (0.16%) with
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serum progesterone level <5 ng/ml , but both of these patients had normally
ri sing ~-HCG levels. Hahlin+l found that no normal intrauterine pregnancy
had both a progesterone level of <30 nmolll (9.4 ng/ml) and an abnormal
increase in ~ -HCG , whereas 72% of ectopic pregnancies and 81% of
spontaneous abortions had both of these laboratory results. The other 28%
of ectopic pregnancies are those with a higher progesterone level and/or
normally increasing ~-HCG levels. These are the pregnancies that are most
likely to contain a living and growing embryo. Ectopic pregnancies with a
li ving embryo have a higher mean ~-HCG level 36 and thus must have a
functioning embryo-trophoblast unit. To also support this concept, Johnson
et al. 45 postulate that the embryo (apart from the trophoblast) plays an
essential role in inducing the production of progesterone by the ovary
whi ch is superimposed on the luteotrophic effect of ~-HCG from the
trophoblast. Kada et al.-l 6 studied ~-HCG levels in early pregnancy in order
to find if the slope of the log of ~-HCG concentrations over time can
di stinguish between normal intrauterine pregnancies, ectopic pregnancies
and spontaneous abortions. The slope of the logarithm of ~-HCG of all
normal pregnancies was greater >0.05 (25 % increase over 2 days), and
42 % of ectopic pregnancies have slopes below this level. Stewart et al. 47
performed a similar type of study, all of their normal intra-uterine
pregnancies had slopes above 0. 10% (60% rise over two days), and 57% of
ectopic pregnancies have slopes below this level. In essence, ectopic
pregnancies that have a living embryo present, behave similarly in
biochemical terms to normal intra-uterine pregnancies. Ectopic pregnancies
that had embryonic death occur, act biochemically similar to spontaneous
abortions. The progesterone level of <5 ng/ml (instead of 9.4 ng/ml) and a
~-HCG increase less than 25 % over two days (instead of 60%)were used
here because this errs on the side of caution. This cliterion excludes those
ectopic pregnancies in which embryonic life is still possible.
This again is not a stand-alone criterion; this is only useful when the
clinical information makes the diagnosis of ectopic pregnancy very likely.
Also, the diagnosis of embryonic death may be made with criteria other
than the one listed above. A conscientious physician may diagnose
embryonic death with the available clinical information of the particular
patient, but this would need to be done on a case-by-case basis. Individual
physicians and hospitals may vary with regard to the reliability of the
diagnostic tests just stated.
Third, let us consider the case where it is uncertain whether
embryonic life or death is present. When the clinical information cannot
determine that embryonic death has OCCUlTed, waiting and further
diagnostic studies would be indicated. If there is doubt whether embryonic
death has occurred, then it should be assumed that embryonic life is still
present.
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The treatment options for ectopic pregnancy should be based on the
presence or absence of embryonic life. If embryonic life is present, total
salpingectomy or partial salpingectomy with tubal re-anastomosis are the
only licit options available. Salpingectomy (partial or total) would be
permissible using the principle of double-effect, and probably makes the
most sense surgically as well. The growth of an ectopic pregnancy with
embryonic cardiac activity probably causes a much more substantial
degree of tubal damage as compared with an anembryonic ectopic/ so
tubal integrity is severely impaired and risk of future ectopic greatly
increased. Salpingectomy in these cases would be the optimum treatment.
Transplantation of the viable ectopic pregnancy into the uterus would be
the best solution, but has had documented success only two times in the
medical literature, as ofthis writing. The limited success of transplantation
may be secondary to the lack of a living embryo present in the majority of
ectopic pregnancies. If embryonic death is present, salpingectomy,
salpingostomy, or methotrexate are all options for the patient, with the
decision to be based on the clinical judgment of the physician. The growth
of an ectopic with very early embryonic demise probably causes much less
tubal damage as compared with a viable ectopic/ so salpingostomy or
methotrexate may prove to be adequate treatment options that also allow
enhanced future fertility. In cases of doubt whether a living embryo is
present, salpingectomy would be the only licit option available.
In conclusion, ectopic pregnancy is an unfortunate event that is
increasing in frequency. In most cases of ectopic pregnancy, an embryo is
not present. In cases where a living embryo is found or we are unable to
determine if a living embryo is present, salpingectomy is the procedure to
be performed. If embryonic death is diagnosed, then licit treatments are
salpingectomy, salpingostomy, or methotrexate.
Transplantation of a living embryo into the uterus is the ideal
procedure, and if perfected, would be a tremendous breakthrough in the
treatment of ectopic pregnancy. Hopefully, success will come soon.
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